Artículos de revistas
Peptides Derived From Phage Display Libraries As Potential Neutralizers Of Shiga Toxin-induced Cytotoxicity In Vitro And In Vivo
Registro en:
Journal Of Applied Microbiology. Blackwell Publishing Ltd, v. 116, n. 5, p. 1322 - 1333, 2014.
13645072
10.1111/jam.12451
2-s2.0-84898452789
Autor
Bernedo-Navarro R.A.
Miyachiro M.M.
Da Silva M.J.
Reis C.F.
Conceicao R.A.
Gatti M.S.V.
Yano T.
Institución
Resumen
Aims: To use the phage display technique to develop peptides with the capability to neutralize the cytotoxicity induced by Stx1 and Stx2 toxins produced by Shiga toxin-producing Escherichia coli (STEC). Methods and Results: The phage display technique permitted the development of three peptides, named PC7-12, P12-26 and PC7-30, which bind to the globotriaosylceramide (Gb3) receptor for Shiga toxins produced by STEC. Moreover, these peptides were capable of competing efficiently with the Shiga toxins for binding to Gb3. The peptides described herein partially inhibited the Stx-induced cytotoxicity of cell-free filtrates of STEC O157 : H7 and purified Stx toxins in Vero cells. The inhibition of lethality induced by Stx toxins in mice indicated that peptide PC7-30 inhibited the lethality caused by Stx1 (2LD50) in mice. Conclusions: The phage display technique permitted the development of peptides that inhibited the cytotoxicity induced by Stx toxins in vitro. Peptide PC7-30 inhibited the lethality of Stx1 in vivo; this molecule would be a promising candidate for the development of therapeutic agents for STEC-related diseases in humans. Significance and Impact of the Study: The selection of Gb3, the common receptor for Stx1 and Stx2, may contribute to the development of efficient neutralizers for both toxins, and our approach would be an interesting alternative for the development of therapeutic molecules for the treatment of diseases caused by STEC strains. © 2014 The Society for Applied Microbiology. 116 5 1322 1333 Camacho, C.J., Katsumata, Y., Ascherman, D.P., Structural and thermodynamic approach to peptide immunogenicity (2008) PLoS Comput Biol, 4, pp. e1000231 Casadevall, A., Passive antibody administration (immediate immunity) as a specific defense against biological weapons (2002) Emerg Infect Dis, 8, pp. 833-841 El Sayed Zaki, M., El-Adrosy, H., Diagnosis of Shiga toxin producing Escherichia coli infection, contribution of genetic amplification technique (2007) Microbes Infect, 9, pp. 200-203 Fuller, C.A., Pellino, C.A., Flagler, M.J., Strasser, J.E., Weiss, A.A., Shiga toxin subtypes display dramatic differences in potency (2011) Infect Immun, 79, pp. 1329-1337 Funke, S.A., Willbold, D., Mirror image phage display - a method to generate d-peptide ligands for use in diagnostic or therapeutical applications (2009) Mol BioSyst, 5, pp. 783-786 Gallegos, K.M., Conrady, D.G., Karve, S.S., Gunasekera, T.S., Herr, A.B., Weiss, A.A., Shiga toxin binding to glycolipids and glycans (2012) PLoS ONE, 7, pp. e30368 Grif, K., Dierich, M.P., Karch, H., Allerberger, F., Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents (1998) Eur J Clin Microbiol Infect Dis, 17, pp. 761-766 Hashimoto, H., Mizukoshi, K., Nishi, M., Kawakita, T., Hasui, S., Kato, Y., Ueno, Y., Takeya, R., Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan (1999) Pediatrics, 103, pp. e2 Heins, S.M., Quax, W.J., Implications of a newly discovered DR5 specific antagonistic peptide for neurodegenerative disorders (2010) Mol Cell Pharmacol, 2, pp. 97-100 Kaper, J.B., Nataro, J.P., Mobley, H.L.T., Pathogenic Escherichia coli (2004) Nat Rev Microbiol, 2, pp. 123-140 Köhler, B., Karch, H., Schmidt, H., Antibacterials that are used as growth promoters in animal husbandry can affect the release of Shiga-toxin-2-converting bacteriophages and Shiga toxin 2 from Escherichia coli strains (2000) Microbiology, 146, pp. 1085-1090 Ladner, R.C., Sato, A.K., Gorzelany, J., De Souza, M., Phage display-derived peptides as therapeutic alternatives to antibodies (2004) Drug Discov Today, 9, pp. 525-529 Lien, S., Lowman, H.B., Therapeutic peptides (2003) Trends Biotechnol, 21, pp. 556-562 Lingwood, C.A., Role of verotoxin receptors in pathogenesis (1996) Trends Microbiol, 4, pp. 147-153 Louise, C.B., Obrig, T.G., Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells (1995) J Infect Dis, 172, pp. 1397-1401 Mantzourani, E., Laimou, D., Matsoukas, M.T., Tselios, T., Peptides as therapeutic agents or drug leads for autoimmune, hormone dependent and cardiovascular diseases (2008) Antiinflamm Antiallergy Agents Med Chem, 7, pp. 294-306 Matise, I., Cornick, N.A., Booher, S.L., Samuel, J.E., Bosworth, B.T., Moon, H.W., Intervention with shiga toxin (stx) antibody after infection by stx-producing Escherichia coli (2001) J Infect Dis, 183, pp. 347-350 McGregor, D.P., Discovering and improving novel peptide therapeutics (2008) Curr Opin Pharmacol, 8, pp. 616-619 Melton-Celsa, A., O'Brien, A., Structure, biology and relative toxicity of Shiga toxin family members for cells and animals (1998) Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains, pp. 121-128. , ed. Kaper, J. and O'Brien, A. Washington, DC: ASM Press Miura, Y., Sakaki, A., Kamihira, M., Iijima, S., Kobayashi, K., A globotriaosylceramide (Gb3Cer) mimic peptide isolated from phage display library expressed strong neutralization to Shiga toxins (2006) Biochim Biophys Acta, 1760, pp. 883-889 Molek, P., Strukelj, B., Bratkovic, T., Peptide phage display as a tool for drug discovery: targeting membrane receptors (2011) Molecules, 16, pp. 857-887 Müthing, J., Schweppe, C.H., Karch, H., Friedrich, A.W., Shiga toxins, glycosphingolipid diversity, and endothelial cell injury (2009) Thromb Haemost, 101, pp. 252-264 Nakajima, H., Kiyokawa, N., Katagiri, Y.U., Taguchi, T., Suzuki, T., Sekino, T., Mimori, K., Ebata, T., Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance (2001) J Biol Chem, 276, pp. 42915-42922 Neri, P., Tokoro, S., Kobayashi, R., Sugiyama, T., Umeda, K., Shimizu, T., Tsuji, T., Kodama, Y., Specific egg yolk immunoglobulin as a new preventive approach for shiga-toxin-mediated diseases (2011) PLoS ONE, 6, pp. e26526 Nishikawa, K., Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli (2011) Arch Immunol Ther Exp, 59, pp. 239-247 Nishikawa, K., Matsuoka, K., Watanabe, M., Igai, K., Hino, K., Nishikawa, K., Yamada, A., Abe, N., Identification of the optimal structure for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation (2005) J Infect Dis, 191, pp. 2097-2105 Nishikawa, K., Watanabe, M., Kita, E., Igai, K., Omata, K., Yaffe, M.B., Natori, Y., A multivalent peptide-library approach identifies a novel Shiga toxin-inhibitor that induces aberrant cellular transport of the toxin (2006) FASEB J, 20, pp. 2597-2599 Nyholm, P.G., Magnusson, G., Zheng, Z., Norel, R., Binnington-Boyd, B., Lingwood, C.A., Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins (1996) Chem Biol, 3, pp. 263-275 Okuda, T., Tokuda, N., Numata, S., Ito, M., Ohta, M., Kawamura, K., Wiels, J., Urano, T., Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins (2006) J Biol Chem, 281, pp. 10230-10235 Olmez, E.O., Akbulut, B.S., Protein-peptide interactions revolutionize drug development, binding protein (2012) Binding Protein, , http://www.intechopen.com/books/binding-protein/protein-peptide-interactions-revolutionize-drug-development, ed. Abdelmohsen, K. Chapter 3. InTech. Available from: Peter, M.G., Lingwood, C.A., Apparent cooperativity in multivalent verotoxin-globotriaosyl ceramide binding: kinetic and saturation binding studies with [125I]verotoxin (2000) Biochim Biophys Acta, 1501, pp. 116-124 Petruzziello-Pellegrini, T.N., Marsden, P.A., Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics (2012) Curr Opin Nephrol Hypertens, 21, pp. 433-440 Rahal, E.A., Kazzi, N., Kanbar, A., Abdelnoor, A.M., Matar, G.M., Role of rifampicin in limiting Escherichia coli O157:H7 shiga-like toxin expression and enhancement of survival of infected BALB/c mice (2011) Int J Antimicrob Agents, 37, pp. 135-139 (2011), Robert Koch Institute. Report: Final Presentation and Evaluation of Epidemiological Findings in the EHEC O104:H4 Outbreak, Germany 2011(1986) SAS User's Guide: Statistics. Version 9.2, , SAS Institute Inc. Cary, NC: SAS Institute Inc Sauter, K.A.D., Melton-Celsa, A.R., Larkin, K., Troxell, M.L., O'Brien, A.D., Magun, B.E., Mouse model of hemolytic-uremic syndrome caused by endotoxin-free shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody (2008) Infect Immun, 76, pp. 4469-4478 Scallan, E., Hoekstra, R.M., Angulo, F.J., Tauxe, R.V., Widdowson, M., Roy, S.L., Jones, J.L., Griffin, P.M., Foodborne illness acquired in the united states-major pathogens (2011) Emerg Infect Dis, 17, pp. 7-15 Scheiring, J., Rosales, A., Zimmerhackl, L.B., Clinical practice: today's understanding of the haemolytic uraemic syndrome (2010) Eur J Pediatr, 169, pp. 7-13 Schmitt, C.K., McKee, M.L., O'Brien, A.D., Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511 (1991) Infect Immun, 59, pp. 1065-1073 Silberstein, C., Copeland, D.P., Chiang, W., Repetto, H.A., Ibarra, C., A glucosylceramide synthase inhibitor prevents the cytotoxic effects of Shiga toxin-2 on human renal tubular epithelial cells (2009) J Epithel Biol Pharmacol, 1, pp. 71-75 Smith, M.J., Melton-Celsa, A.R., Sinclair, J.F., Carvalho, H.M., Robinson, C.M., O'Brien, A.D., Monoclonal antibody 11E10, which neutralizes shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin (2009) Infect Immun, 77, pp. 2730-2740 Soltyk, A.M., MacKenzie, C.R.V., Wolski, M., Hirama, T., Kitov, P.I., Bundle, D.R., Brunton, J.L., A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1 (2002) J Biol Chem, 277, pp. 5351-5359 Stearns-Kurosawa, D.J., Collins, V., Freeman, S., Tesh, V.L., Kurosawa, S., Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli (2010) Infect Immun, 78, pp. 2497-2504 Stone, E., Hirama, T., Chen, W., Soltyk, A.L., Brunton, J., MacKenzie, C.R., Zhang, J., A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1 (2007) Mol Immunol, 44, pp. 2487-2491 Strockbine, N.A., Marques, L.R.M., Newland, J.W., Smith, H.W., Holmes, R.K., O'Brien, A.D., Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities (1986) Infect Immun, 53, pp. 135-140 Sukhumungoon, P., Mittraparp-Arthorn, P., Pomwised, R., Charernjiratragul, W., Vuddhakul, V., High concentration of Shiga toxin 1-producing Escherichia coli isolated from southern Thailand (2011) Int Food Res J, 18, pp. 683-688 Tarr, P.I., Gordon, C.A., Chandler, W.L., Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome (2005) Lancet, 365, pp. 1073-1086 Tesh, V.L., Burris, J.A., Owens, J.W., Gordon, V.M., Wadolkowski, E.A., O'Brien, A.D., Samuel, J.E., Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice (1993) Infect Immun, 61, pp. 3392-3402 Trachtman, H., Austin, C., Lewinski, M., Stahl, R.A.K., Renal and neurological involvement in typical Shiga toxin-associated HUS (2012) Nat Rev Nephrol, 8, pp. 658-669 Vlieghe, P., Lisowski, V., Martinez, J., Khrestchatisky, M., Synthetic therapeutic peptides: science and market (2010) Drug Discov Today, 15, pp. 40-56 Wen, S.X., Teel, L.D., Judge, N.A., O'Brien, A.D., Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge (2006) Vaccine, 24, pp. 1142-1148 Xia, X., Meng, J., McDermott, P.F., Ayers, S., Blickenstaff, K., Tran, T.T., Abbott, J., Zheng, J., Presence and characterization of Shiga toxin-producing Escherichia coli and other potentially diarrheagenic E. coli strains in retail meats (2010) Appl Environ Microbiol, 76, pp. 1709-1717 Xu, H., Di, B., Pan, Y.X., Qiu, L.W., Wang, Y.D., Hao, W., He, L.J., Yuen, K.Y., Serotype 1-specific monoclonal antibody-based antigen capture immunoassay for detection of circulating nonstructural protein NS1: implications for early diagnosis and serotyping of dengue virus infections (2006) J Clin Microbiol, 44, pp. 2872-2878 Yamada, Y., Miura, Y., Sakaki, A., Yoshida, T., Kobayashi, K., Design of multifunctional peptides expressing both antimicrobial activity and Shiga toxin neutralization activity (2006) Bioorg Med Chem, 14, pp. 77-82